Abstract
Tissue inhibitor of metalloproteinase (TIMP) has been reported to inhibit tumour invasion through an inactivation of matrix metalloproteinase (MMP) both in vitro and in vivo. Among the TIMP family, TIMP-1 possesses not only proteinase inhibitory activity but also a growth-promoting function. However, the significance of the expression of TIMP-1 in human gastric carcinoma tissue has yet to be clarified. In 50 examined cases of gastric carcinoma, 44 (88%) cases showed a higher expression of TIMP-1 mRNA in the biopsy samples from the tumour tissue (T) than in the biopsy samples from the corresponding normal tissue (N), as determined by semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR). In a multivariate analysis, the T/N ratio of TIMP-1 mRNA was found to be an independent factor influencing the depth of tumour invasion and was the second most important factor in determining the prognosis of patients. As RT-PCR assay can be performed on biopsy specimens obtained before surgery, an evaluation of the TIMP-1 expression in biopsy specimens by RT-PCR may thus provide useful preoperative information on tumour aggressiveness.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mimori, K., Mori, M., Shiraishi, T. et al. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer 76, 531–536 (1997). https://doi.org/10.1038/bjc.1997.420
Issue Date:
DOI: https://doi.org/10.1038/bjc.1997.420
This article is cited by
-
Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+Â metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab)
Breast Cancer Research and Treatment (2017)
-
mRNA profiling of the cancer degradome in oesophago–gastric adenocarcinoma
British Journal of Cancer (2012)
-
Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer
BMC Cancer (2010)
-
Abnormal expression of TRIB3 in colorectal cancer: a novel marker for prognosis
British Journal of Cancer (2009)
-
Impact of plasma tissue inhibitor of metalloproteinase-1 on long-term survival in patients with gastric cancer
Gastric Cancer (2009)